12790 EL CAMINO REAL, SUITE 200, SAN DIEGO, CA
Merger Completed: Ventyx Biosciences Merges with Eli Lilly
Ventyx Biosciences Enters Merger Agreement with Eli Lilly; Special Meeting Held
Other Events
2026 Cash Bonus Awards Granted to Key Executives at Ventyx Biosciences
To acquire to advance oral therapies targeting inflammatory-mediated diseases
Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Investor Presentation
Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Q3
Q2
Q1
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Merger Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notification Filed by a National Security Exchange
S-8 POS
Post-Effective Amendment to Registration Statement
PREM14A